We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

58 hedge funds and large institutions have $65.6M invested in Lineage Cell Therapeutics in 2013 Q2 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

36.82% more ownership

Funds ownership: 0% → 36.82% (+37%)

75% less call options, than puts

Call options by funds: $196K | Put options by funds: $775K

Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.89%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
58
Increased
–
Reduced
–
Closed
–
Calls
$196K
Puts
$775K
Net Calls
-$579K
Net Calls Change
-$579K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

LCTX Hedge Fund Activity: Q2 2013 in Review

58 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2013, worth a combined $65.6M.

Buyers outnumbered sellers: 58 funds opened new LCTX positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.

  • 58 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $65.6M of Lineage Cell Therapeutics stock for Q2 2013.
  • 58 funds opened new Lineage Cell Therapeutics positions in Q2 2013 and 0 closed out, a net change of +58 holders.

Based on aggregated 13F filings for Q2 2013.